VANCOUVER, July 6, 2017 /CNW/ - Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has received approval from the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade Cannabidiol (CBD) product, Isoderm™. This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists.
Isodiol International CEO Marcos Agramont stated, "We had initially anticipated this process to lead us into the third quarter, however receiving the first approval in a few months shows the quality and market demand for our Isoderm™ product. We anticipate additional product and medical indication approvals to continue over the coming weeks and months. We will strengthen our distribution relationships in the region and continue working towards receiving product approvals in other jurisdictions. We will continue to be proactive and mitigate the regulatory risk in North America by increasing our footprint in countries that have approved medical CBD. By increasing our global presence, we feel we will be in a position to influence the regulatory and legal framework of this movement into a sustainable industry domestically in Canada and the US."
Additional information will be provided in the coming weeks around the progress of distribution partnerships.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
CEO & Director
Join Us On Face Book:
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE Isodiol International Inc.
For further information: CORPORATE MEDIA: firstname.lastname@example.org, www.isodiol.com